27.44 USD
-0.17 (-0.62%)
At close: Jan 30, 2026
27.44 USD
0 (0%)
After Hours: 1/30/2026, 8:00:00 PM
Overall AGIO gets a fundamental rating of 4 out of 10. We evaluated AGIO against 525 industry peers in the Biotechnology industry. AGIO has a great financial health rating, but its profitability evaluates not so good. AGIO is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year AGIO has reported negative net income.
- AGIO had a negative operating cash flow in the past year.
- The reported net income has been mixed in the past 5 years: AGIO reported negative net income in multiple years.
- AGIO had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- The Return On Assets of AGIO (-28.96%) is better than 67.81% of its industry peers.
- With a decent Return On Equity value of -31.24%, AGIO is doing good in the industry, outperforming 75.43% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -28.96% | ||
| ROE | -31.24% | ||
| ROIC | N/A |
ROA(3y)-5.26%
ROA(5y)11.49%
ROE(3y)-6.92%
ROE(5y)4.3%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- With an excellent Gross Margin value of 87.22%, AGIO belongs to the best of the industry, outperforming 89.71% of the companies in the same industry.
- AGIO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 87.22% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- AGIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for AGIO has been increased compared to 1 year ago.
- AGIO has less shares outstanding than it did 5 years ago.
- There is no outstanding debt for AGIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- AGIO has an Altman-Z score of 8.80. This indicates that AGIO is financially healthy and has little risk of bankruptcy at the moment.
- The Altman-Z score of AGIO (8.80) is better than 80.57% of its industry peers.
- There is no outstanding debt for AGIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 8.8 |
ROIC/WACCN/A
WACC8.88%
2.3 Liquidity
- A Current Ratio of 13.82 indicates that AGIO has no problem at all paying its short term obligations.
- AGIO has a Current ratio of 13.82. This is amongst the best in the industry. AGIO outperforms 90.10% of its industry peers.
- A Quick Ratio of 13.39 indicates that AGIO has no problem at all paying its short term obligations.
- AGIO has a Quick ratio of 13.39. This is amongst the best in the industry. AGIO outperforms 89.52% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 13.82 | ||
| Quick Ratio | 13.39 |
3. Growth
3.1 Past
- AGIO shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 7.92%.
- AGIO shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -24.03% yearly.
- AGIO shows a strong growth in Revenue. In the last year, the Revenue has grown by 36.26%.
EPS 1Y (TTM)7.92%
EPS 3Y-24.03%
EPS 5YN/A
EPS Q2Q%26.32%
Revenue 1Y (TTM)36.26%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%43.69%
3.2 Future
- AGIO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.13% yearly.
- AGIO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 86.69% yearly.
EPS Next Y-3.08%
EPS Next 2Y3.13%
EPS Next 3Y8.25%
EPS Next 5Y16.13%
Revenue Next Year30.21%
Revenue Next 2Y74.35%
Revenue Next 3Y92.31%
Revenue Next 5Y86.69%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- AGIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year AGIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.13%
EPS Next 3Y8.25%
5. Dividend
5.1 Amount
- No dividends for AGIO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
AGIOS PHARMACEUTICALS INC / AGIO FAQ
What is the ChartMill fundamental rating of AGIOS PHARMACEUTICALS INC (AGIO) stock?
ChartMill assigns a fundamental rating of 4 / 10 to AGIO.
What is the valuation status of AGIOS PHARMACEUTICALS INC (AGIO) stock?
ChartMill assigns a valuation rating of 0 / 10 to AGIOS PHARMACEUTICALS INC (AGIO). This can be considered as Overvalued.
Can you provide the profitability details for AGIOS PHARMACEUTICALS INC?
AGIOS PHARMACEUTICALS INC (AGIO) has a profitability rating of 2 / 10.